Topoisomerase I activity and sensitivity to camptothecin in breast cancer-derived cells: a comparative study

BACKGROUND: Camptothecin (CPT) and its derivatives are currently used as second- or third-line treatment for patients with endocrine-resistant breast cancer (BC). These drugs convert nuclear enzyme DNA topoisomerase I (TOP1) to a cell poison with the potential to damage DNA by increasing the half-li...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:BMC Cancer
Main Authors: Tesauro, Cinzia, Simonsen, Anne Katrine, Andersen, Marie Bech, Petersen, Kamilla Wandsoe, Kristoffersen, Emil Laust, Algreen, Line, Hansen, Noriko Yokoyama, Andersen, Anne Bech, Jakobsen, Ann Katrine, Stougaard, Magnus, Gromov, Pavel, Knudsen, Birgitta R., Gromova, Irina
פורמט: Artigo
שפה:Inglês
יצא לאור: BioMed Central 2019
נושאים:
Research Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6884793/
https://ncbi.nlm.nih.gov/pubmed/31783818
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-6371-0
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים